A Recent Advance in the Closure of Skin Wounds on Fragile Skin.

The delicate nature of the skin in elderly patients poses a difficult challenge to healthcare providers. Emergency departments are frequently presented with traumatic skin tears and soft tissue avulsions in this group of patients. Procedures aimed at closure of these types of wounds often result in worsening of the tears.

Which Country is Truly Developed? COVID-19 has Answered the Question.

The developed countries of the world were ill-prepared for the pandemic that they have suffered. When we compare developed to developing countries, the sophisticated parameters we use do not necessarily address the weaknesses in the healthcare systems of developed countries that make them susceptible to crises like the present pandemic. We strongly suggest that better preparation for such events is necessary for a country to be considered developed.

An Innovative Advance in Non-invasive Wound Closure: A New Paradigm.

Injury is the leading health and readiness threat to the armed forces, with two million instances per year; therefore, innovating wound care solutions can help improve readiness. The DermaClip Skin Closure Device is a new, non-invasive, painless, and easy-to-apply wound closure device that does not require either needles or painful anesthesia injections or create additional damage to the wounded area. The efficacy of the device was tested in a 120-patient trial, composed of 60 experimental cases and 60 control cases.

Conservative management of pelvic abscess following sacrocolpopexy: a report of three cases and review of the literature.

Introduction And Hypothesis: After sacrocolpopexy, intra-abdominal pelvic abscesses are often managed with intravenous antibiotics, excision of the mesh involved, and debridement of compromised tissue.

Methods And Results: Three cases of successful management of pelvic abscesses after sacrocolpopexy using long-term antibiotics and percutaneous drainage of intra-abdominal abscesses without removing the mesh are presented.

Conclusions: In selected patients who have undergone sacrocolpopexy, with careful counseling, conservative management of pelvic abscesses with percutaneous drainage and long-term antibiotic treatment without the surgical excision of the mesh may play a role.

Protein-losing enteropathy in ulcerative colitis.

Protein-losing enteropathy (PLE) is a debilitating potential complication of ulcerative colitis (UC). We report a case of PLE in a 26-year-old male patient with UC. The patient lost 50 pounds in the setting of a UC flare and was found to have an albumin level of 1.

Healthcare's ascension to patient-centered genomic care.

The future of healthcare in the 21st century will be patient-centered genomic care. These two previously disparate fields now stand to help revolutionize the way in which we provide healthcare. Preventative medicine guided by genomic information and patient preference will enable further reductions in common chronic diseases, especially with the significant aging population.

Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients.

Clinical data were evaluated from an open-label, single-center, pilot study in patients with chronic refractory depression. The primary efficacy criterion was the change from baseline using the Montgomery-Asberg Depression Rating Scale. The secondary efficacy criteria were the 17-item Hamilton Depression Rating Scale and the Clinical Global Impression-Improvement scale.

Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression.

Background: Nemifitide is a novel peptide analog of melanocyte-inhibiting factor (MIF) that has been reported to relieve depressive symptoms in a very short period.

Objectives: The Flinders Sensitive Line (FSL) rat, a genetic animal model of depression with innate exaggerated immobility in the forced swim test, was used to obtain more detailed information about the antidepressant-like effects of nemifitide.

Methods: The FSL rats were treated chronically with various doses of nemifitide or reference antidepressants desipramine and fluoxetine for 5 or 14 days and the forced swim test was conducted 22-24 h after the last treatment.

Clinical effectiveness of nemifitide, a novel pentapeptide antidepressant, in depressed outpatients: comparison of follow-up re-treatment with initial treatment.

Data from two Phase 2 clinical studies with nemifitide, a novel pentapeptide antidepressant, were evaluated. The initial double-blind, placebo-controlled study was performed on outpatients with DSM-IV criteria for major depressive disorder. An open-label extension study enrolled subjects either completing or having been discontinued due to lack of efficacy during the follow-up period of the initial study.